Thermo Fisher Scientific subsidiary One Lambda has introduced a new LABScreen Multi assay to detect HNA-3 and HLA.


The FDA cleared and CE marked LABScreen Multi screening kit can process up to 96 samples on a single plate in about four hours and multi plates can be processed simultaneously, making it suitable for clinical labs processing large amount of samples.

Seattle Bloodworks Northwest’ HLA Laboratory co-director and clinical consultant Dr Karen Nelson said: "TRALI is difficult to diagnose and treat. Transfusion centers need an assay that is FDA cleared, highly specific, able to detect antibodies to both HNA and HLA and automatable.

"The LABScreen Multi kit from One Lambda meets these criteria."

Both anti-HLA and anti-HNA antibodies were implicated in the clinical cases of transfusion-related acute lung injury (TRALI), which is a serious complication from blood transfusions that can cause pulmonary edema and is the leading cause of transfusion-related death.

Using the high-throughput Luminex platform, the new LABScreen Multi antibody screening kit simultaneously detects HLA Class I, HLA Class II and HNA 1a, 1b, 1c, 2, 3a, 3b, 4a, 5a and 5b antibodies.

The test provides an efficient method for antibody screening compared against conventional testing methods for neutrophil antibodies. With the help of HLA Fusion software, it is easy to interpret data for both antigen groups.

One Lambda develops and markets various HLA typing and antibody detection tests utilizing serological, molecular, ELISA, Flow and Luminex technologies. It also produces laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations.

Image: LABScreen Multi is a screening tool for antibodies again both the human leukocyte antigen (HLA) and human neutrophil antigens (HNA). Photo: courtesy of Thermo Fisher Scientific Inc.